RESEARCH PAPER
Echocardiographic abnormalities and disease severity (based on CD4 count) in treatment-naive HIV positive patients
 
More details
Hide details
 
Submission date: 2016-07-10
 
 
Final revision date: 2017-03-29
 
 
Acceptance date: 2017-05-19
 
 
Publication date: 2017-10-08
 
 
HIV & AIDS Review 2017;16(3):169-175
 
KEYWORDS
TOPICS
ABSTRACT
Purpose: Human immunodeficiency virus (HIV) infection may be associated with cardiac abnormalities. These abnormalities appear to be more frequent with disease progression. This study sought to examine the relationship between HIV disease severity in treatment-naive patients and cardiac abnormalities identified by echocardiography.
Material and methods: 100 HIV-positive, treatment-naive patients, comprising 53 patients with CD4 count < 200/µl (AIDS group) and 47 patients with CD4 count ≥ 200/µl (non-AIDS group) without any traditional risk factors for cardiac disease were recruited for the study. Both groups had clinical and echocardiographic evaluation for cardiac abnormalities.
Results: Of the 53 patients in the AIDS group, 11.5% had dilated cardiomyopathy (DCM), compared with none in the non-AIDS group (p = 0.018). Systolic dysfunction was higher in the AIDS group when compared with the non-AIDS group (42.3% and 17.0%, respectively; p = 0.006). Also, those in the AIDS had a significantly higher left ventricular end diastolic diameter index when compared with the non-AIDS group (2.87 ± 0.37 and 2.67 ± 0.29, respectively; p = 0.004). Furthermore, moderate to severe pericardial effusion was more frequent in the AIDS group, when compared with non-AIDS group (15.38% and 2.12%, respectively; p = 0.045). Diastolic dysfunction was also more frequent in AIDS group, although this did not achieve statistical significance (34.64% and 29.78%, respectively; p = 0.61).
Conclusion: Cardiac abnormalities are more frequent with disease progression in HIV infected patients. Patients with more advanced disease (CD4 < 200/µl) had significantly more frequent systolic dysfunction, DCM, larger left ventricular dimension, and moderate to severe pericardial effusion than those with CD4 ≥ 200/µl.
REFERENCES (45)
1.
Prendergast BD. HIV and cardiovascular medicine. Heart 2003; 89: 793-800.
 
2.
Busari OA, Opadijo OG, Adeyemi OA. Cardiac diseases in HIV and AIDS. Internet J Cardiol 2008; 5; doi: 10.5580/216.
 
3.
Barbaro G. Cardiovascular manifestation of HIV infection. J R Soc Med 2001; 94: 384-390.
 
4.
Olusegun-Joseph DA, Ajuluchukwu JNA, Okany CC, et al. The heart and HIV/AIDS. Internet J Cardiol 2010; 9; doi: 10.5580/123e.
 
5.
Rerkpattanapipat P, Wongpraprut N, Jacobs L, et al. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160: 602-608.
 
6.
Sani MU, Okeahialam BN. Epidemiology and Pathogenesis of Human Immunodeficiency Virus (HIV). Related heart disease: A review. Niger J Med 2005; 14: 255-260.
 
7.
Dupe MP, Lipshultz SE, FichtenbaumCJ, et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118: e36-40.
 
8.
Lipshultz SE, Fisher SD, Lai WW, et al. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 2003; 17 (Suppl 1): S96-122.
 
9.
Nzuobontane D, Blackett KN, Kuaban C. Cardiac Involvement in HIV Infected people in Yaounde Cameroon. Postgrad Med J 2002; 78: 678-681.
 
10.
Milei J, Grana D, Fernandez A, et al. Cardiac involvement in Acquired Immune Deficiency Syndrome – a review to push action. Clin Cardiol 1998; 21: 465-472.
 
11.
Hecht SR, Berger M, van Tosh A, et al. Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome: an echocardiographic study. Chest 1989; 96: 805-808.
 
12.
Barbaro G, Di Lorenzo G, Grisorio B, et al. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998; 14: 1071-1077.
 
13.
Chang WT, Wu CC, Hung CC, et al. Left ventricular dysfunction is associated with CD4 lymphocyte count rather than opportunistic infection in human immunodeficiency virus infection. J Formos Med Assoc 2003; 102: 158-163.
 
14.
Sani MU. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr 2008; 120: 77-87.
 
15.
Gopal M, Bhaskaran A, Barbagelata A. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev 2009; 5: 149-154.
 
16.
MacCarthy S, Bangsberg DR, Fink G, et al. Late Presentation to HIV/AIDS Testing, Treatment or Continued Care. Clarifying the Use of CD4 Evaluation in the Consensus Definition. HIV Medicine 2014; 15: 130-134.
 
17.
Drain PK, Losina E, Parker G, et al. Risk factors for late-stage hiv disease presentation at initial hiv diagnosis in Durban, South Africa. PLoS One 2013; 8: e55305.
 
18.
Agaba PA, Meloni ST, Sule HM, et al. Patients who present late to HIV care and associated risk factors in Nigeria. HIV Med 2014; 15: 396-405.
 
19.
Feigenbaum H. Echocardiography. Lippincott William and Wilkins, Philadelphia 2005; 138-180.
 
20.
Henry WL, De Maria A, Gramiak R, et al. Report of the American Society of Echocardiography committee on nomenclature and standards in 2D echocardiography. Circulation 1980; 62: 212-217.
 
21.
Longo-Mbenza B, Seghers L, Vita E, et al. Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart 1998; 80: 184-189.
 
22.
Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
 
23.
Chariot P, Perchert H, Monnet I. Dilated cardiomyopathy in HIV patients. N Engl J Med 1999; 340: 732-735.
 
24.
Longo-Mbenza B, Seghers KV, Phuati M, et al. Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 1998; 64: 63-73.
 
25.
Currie PF, Jacob AJ, Foreman AR, et al. Heart muscle disease related to HIV infection; prognostic implications. Br Med J 1994; 390: 1605-1607.
 
26.
Hakim JG, Matenga JA, Siziya S. Myocardial dysfunction in HIV infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. Heart 1996; 76: 161-165.
 
27.
Taylor D. Diastolic function, the necessary basics. J Diagnostic Med Sonogr 2006; 22: 99-108.
 
28.
Olusegun-Joseph DA, Ajuluchukwu JNA, Okany CC, et al. Echocardiographic patterns in treatment-naïve HIV-positive patients in Lagos, south-west Nigeria. Cardiovasc J Afr 2012; 23: e1–6.
 
29.
Silva-Cardoso J, Moura B, Martins L, et al. Pericardial involvement in Human Immunodeficiency Virus infection. Chest 1999; 115: 418-422.
 
30.
Okeahialam BN, Anjorin FL. Echocardiographic study of the heart in AIDS. The Jos experience. Trop Card 2000; 26: 3-6.
 
31.
Danbauchi SS, Sani SG, Alhassan MA, et al. Cardiac manifestations of stage III/IV HIV/AIDS compared to subjects on ARV in Zaria, Nigeria. Nig J Cardiol 2006; 3: 5-10.
 
32.
Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS: Incidence and Survival. Circulation 1995; 92: 3229-3234.
 
33.
Silva-Cardoso J, Moura B, Martins L, et al. Left ventricular dysfunction in HIV-infected patients. Int J Cardiol 1998; 63: 37-45.
 
34.
Lumsden RH, Bloomfield GS. The Causes of HIV-Associated Cardiomyopathy: A Tale of Two Worlds. Biomed Res Int 2016; doi: 10.1155/2016/8196560.
 
35.
Ntusi NAB, Ntsekhe M. Human immunodeficiency virus-associated heart failure in sub-Saharan Africa: evolution in the epidemiology, pathophysiology, and clinical manifestations in the antiretroviral era. ESC Heart Failure 2016; 3: 158-167.
 
36.
Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children. The prospective P2C2 HIV multicenter study. Circulation 2000; 102: 1542-1548.
 
37.
Barbaro G. Cardiovascular manifestation of HIV infection. Circulation 2002; 106: 1420-1425.
 
38.
Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001; 1: 115-124.
 
39.
Coudray N, De Zuttere D, Force G, et al. Left ventricular diastolic dysfunction in asymptomatic and symptomatic human immunodeficiency virus carriers: an echocardiographic study. Eur Heart J 1995; 16: 61-67.
 
40.
Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3: 132-139.
 
41.
Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J 2013; doi:10.1093/eurheartj/eht388.
 
42.
Ntsekhe M, Hakim J. Impact of human immunodeficiency virus infection on cardiovascular disease in Africa. Circulation 2005; 112: 3602-3607.
 
43.
Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40: 282-284.
 
44.
Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Rev Cardiol 2009; 6: 120-127.
 
45.
Battegay M, Fehr J, Fluckiger U, et al. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 2008; 62: 41-44.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top